04.04.2017 • Topics

Open to New Ways of Doing Business

Christopher Erbslöh, managing director, C.H. Erbsloeh
Christopher Erbslöh, managing director, C.H. Erbsloeh

“Today’s digital transformation debate bewilders me somewhat, as this is not a new topic but one that has been around for more than 40 years. The only difference is the speed at which new and updated technology is available. Today, as back in the 1970s, the only right answer to the digital transformation debate is: “Yes, we should introduce and use any new technology that advances our business at a justifiable cost.”

For specialty distributors like C.H. Erbslöh we expect positive effects from new technologies mainly in administrative processes but also in the supply chain. We, however, neither see our workforce being reduced nor a full transformation of our point of sales to an e-commerce platform in the next 5 to 8 years. Having said that, it is obvious that some product categories surely will be sold through e-commerce platforms in the near future. Still, we do not have a special digital agenda as new ideas, technologies and ways of doing business always have been on our agenda.”

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read